Nxera Pharma Co., Ltd. (FRA:JSS)

Nxera Pharma Statistics

Total Valuation

Nxera Pharma has a market cap or net worth of EUR 444.74 million. The enterprise value is 647.53 million.

Market Cap	444.74M
Enterprise Value	647.53M

Important Dates

The last earnings date was Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	90.49M
Shares Outstanding	n/a
Shares Change (YoY)	+0.61%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	73.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.76
PB Ratio	1.34
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-9.51
EV / Sales	3.99
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-38.26

Financial Position

The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.94.

Current Ratio	2.54
Quick Ratio	1.76
Debt / Equity	0.94
Debt / EBITDA	n/a
Debt / FCF	-18.41
Interest Coverage	-1.13

Financial Efficiency

Return on equity (ROE) is -19.35% and return on invested capital (ROIC) is -8.53%.

Return on Equity (ROE)	-19.35%
Return on Assets (ROA)	-3.70%
Return on Invested Capital (ROIC)	-8.53%
Return on Capital Employed (ROCE)	-7.22%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	421,136
Profits Per Employee	-178,181
Employee Count	382
Asset Turnover	0.21
Inventory Turnover	0.81

Taxes

Income Tax	-13.15M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.28% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-10.28%
50-Day Moving Average	4.54
200-Day Moving Average	5.01
Relative Strength Index (RSI)	55.77
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Nxera Pharma had revenue of EUR 160.87 million and -68.07 million in losses. Loss per share was -0.75.

Revenue	160.87M
Gross Profit	116.34M
Operating Income	-45.97M
Pretax Income	-81.21M
Net Income	-68.07M
EBITDA	-22.26M
EBIT	-45.97M
Loss Per Share	-0.75

Balance Sheet

The company has 110.63 million in cash and 311.69 million in debt, with a net cash position of -201.07 million.

Cash & Cash Equivalents	110.63M
Total Debt	311.69M
Net Cash	-201.07M
Net Cash Per Share	n/a
Equity (Book Value)	331.35M
Book Value Per Share	3.66
Working Capital	146.48M

Cash Flow

In the last 12 months, operating cash flow was -14.49 million and capital expenditures -2.43 million, giving a free cash flow of -16.93 million.

Operating Cash Flow	-14.49M
Capital Expenditures	-2.43M
Free Cash Flow	-16.93M
FCF Per Share	n/a

Margins

Gross margin is 72.32%, with operating and profit margins of -28.58% and -42.31%.

Gross Margin	72.32%
Operating Margin	-28.58%
Pretax Margin	-50.48%
Profit Margin	-42.31%
EBITDA Margin	-13.83%
EBIT Margin	-28.58%
FCF Margin	n/a

Dividends & Yields

Nxera Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.61%
Shareholder Yield	-0.61%
Earnings Yield	-15.30%
FCF Yield	-3.81%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Nxera Pharma has an Altman Z-Score of 0.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.73
Piotroski F-Score	3